Publicaciones en las que colabora con Eva Poveda López (32)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  4. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies

    Journal of Medical Virology, Vol. 90, Núm. 6, pp. 1094-1098

2017

  1. Cancer incidence in persons living with HIV

    Clinical Infectious Diseases

  2. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

    Journal of Medical Virology, Vol. 89, Núm. 7, pp. 1304-1308

  3. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

  4. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

  5. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected

    AIDS, Vol. 31, Núm. 8, pp. 1099-1107

  6. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV

    HIV Medicine, Vol. 18, Núm. 9, pp. 685-689

  7. Nuevos modelos para una educación científica inclusiva a través de la televisión y medios digitales

    Transformando dende a universidade: V Xornada Universitaria Galega en Xénero, XUGeX

  8. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: Potential role as a biomarker of HIV replication

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 11, pp. 3159-3162

  9. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients

    Journal of Clinical Virology, Vol. 88, pp. 58-61

  10. Tendencia de las hospitalizaciones, reingresos y mortalidad intrahospitalaria en los pacientes infectados por VIH entre 1993-2013: impacto de la coinfección por el virus de la hepatitis C

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 1, pp. 20-26

  11. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: Impact for monitoring and optimizing treatment duration

    European Journal of Gastroenterology and Hepatology, Vol. 29, Núm. 7, pp. 781-785